Myeloma Center

Bibliography

Found 21 results

Author Title [ Type

] Year

Filters: Keyword is Antineoplastic Combined Chemotherapy Protocols and Author is Niesvizky, Ruben [Clear All Filters]

Journal Article

Mark T, Jayabalan D, Coleman M, Pearse RN, Y Wang L, Lent R, Christos PJ, Lee JW, Agrawal YP, Matthew S et al.. 2008. Atypical serum immunofixation patterns frequently emerge in immunomodulatory therapy and are associated with a high degree of response in multiple myeloma.. Br J Haematol. 143(5):654-60.

Niesvizky R, Coleman M, Mark T. 2010. Best practices in the management of newly diagnosed multiple myeloma patients who will not undergo transplant.. Oncology (Williston Park). 24(3 Suppl 2):14-21.

Niesvizky R, Jayabalan DS, Christos PJ, Furst JR, Naib T, Ely S, Jalbrzikowski J, Pearse RN, Zafar F, Pekle K et al.. 2008. BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma.. Blood. 111(3):1101-9.

A Stewart K, S Rajkumar V, Dimopoulos MA, Masszi T, Spicka I, Oriol A, Hajek R, Rosiñol L, Siegel DS, Mihaylov GG et al.. 2015. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.. N Engl J Med. 372(2):142-52.

Dimopoulos MA, A Stewart K, Masszi T, Spicka I, Oriol A, Hajek R, Rosiñol L, Siegel D, Mihaylov GG, Goranova-Marinova V et al.. 2017. Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study.. Br J Haematol. 177(3):404-413.

Dimopoulos MA, Goldschmidt H, Niesvizky R, Joshua D, Chng W-J, Oriol A, Orlowski RZ, Ludwig H, Facon T, Hajek R et al.. 2017. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial.. Lancet Oncol. 18(10):1327-1337.

Avet-Loiseau H, Fonseca R, Siegel D, Dimopoulos MA, Spicka I, Masszi T, Hajek R, Rosiñol L, Goranova-Marinova V, Mihaylov G et al.. 2016. Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma.. Blood. 128(9):1174-80.

Gay F, S Rajkumar V, Coleman M, Kumar S, Mark T, Dispenzieri A, Pearse R, Gertz MA, Leonard J, Lacy MQ et al.. 2010. Clarithromycin (Biaxin)-lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (Rd) for newly diagnosed myeloma.. Am J Hematol. 85(9):664-9.

Dimopoulos MA, Terpos E, Niesvizky R, Palumbo A. 2015. Clinical characteristics of patients with relapsed multiple myeloma.. Cancer Treat Rev. 41(10):827-35.

Niesvizky R, Flinn IW, Rifkin R, Gabrail N, Charu V, Clowney B, Essell J, Gaffar Y, Warr T, Neuwirth R et al.. 2015. Community-Based Phase IIIB Trial of Three UPFRONT Bortezomib-Based Myeloma Regimens.. J Clin Oncol. 33(33):3921-9.

A Stewart K, Dimopoulos MA, Masszi T, Spicka I, Oriol A, Hajek R, Rosiñol L, Siegel DS, Niesvizky R, Jakubowiak AJ et al.. 2016. Health-Related Quality-of-Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma.. J Clin Oncol. 34(32):3921-3930.

Dimopoulos MA, Terpos E, Niesvizky R. 2013. How lenalidomide is changing the treatment of patients with multiple myeloma.. Crit Rev Oncol Hematol. 88 Suppl 1:S23-35.

Niesvizky R, Naib T, Christos PJ, Jayabalan D, Furst JR, Jalbrzikowski J, Zafar F, Mark T, Lent R, Pearse RN et al.. 2007. Lenalidomide-induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment-naïve patients undergoing front-line lenalidomide and dexamethasone therapy.. Br J Haematol. 138(5):640-3.

Mark T, Niesvizky R, Coleman M. 2009. Novel agents in myeloma: an exciting saga.. Cancer. 115(2):236-42.

Mark TM, Reid W, Niesvizky R, Gergis U, Pearse R, Mayer S, Greenberg J, Coleman M, van Besien K, Shore T. 2013. A phase 1 study of bendamustine and melphalan conditioning for autologous stem cell transplantation in multiple myeloma.. Biol Blood Marrow Transplant. 19(5):831-7.

Niesvizky R, Badros AZ, Costa LJ, Ely SA, Singhal SB, Stadtmauer EA, Haideri NA, Yacoub A, Hess G, Lentzsch S et al.. 2015. Phase 1/2 study of cyclin-dependent kinase (CDK)4/6 inhibitor palbociclib (PD-0332991) with bortezomib and dexamethasone in relapsed/refractory multiple myeloma.. Leuk Lymphoma. 56(12):3320-8.

Wang M, Martin T, Bensinger W, Alsina M, Siegel DS, Kavalerchik E, Huang M, Orlowski RZ, Niesvizky R. 2013. Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma.. Blood. 122(18):3122-8.

Mark TM, Coleman M, Niesvizky R. 2014. Preclinical and clinical results with pomalidomide in the treatment of relapsed/refractory multiple myeloma.. Leuk Res. 38(5):517-24.

Kumar SK, Berdeja JG, Niesvizky R, Lonial S, Laubach JP, Hamadani M, A Stewart K, Hari P, Roy V, Vescio R et al.. 2014. Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study.. Lancet Oncol. 15(13):1503-12.

Mark T, Stern J, Furst JR, Jayabalan D, Zafar F, Larow A, Pearse RN, Harpel J, Shore T, Schuster MW et al.. 2008. Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma.. Biol Blood Marrow Transplant. 14(7):795-8.

Mark TM, Bowman IA, Rossi AC, Shah M, Rodriguez M, Quinn R, Pearse RN, Zafar F, Pekle K, Jayabalan D et al.. 2014. Thalidomide, clarithromycin, lenalidomide and dexamethasone therapy in newly diagnosed, symptomatic multiple myeloma.. Leuk Lymphoma. 55(12):2842-9.